Skip to main content

Table 1 Patient characteristics

From: Effect of laminar air flow and building construction on aspergillosis in acute leukemia patients: a retrospective cohort study

Characteristics whole period phase A phase B phase C phase D p value
sex
 female 52 16 12 17 7 0.059
 male 72 20 6 26 20  
age (years) 15–75 (52.0) 25–73 (56.5) 19–71 (46.5) 18–75 (51) 15–70 (52) 0.763
  > median(53–75) 59 19 8 19 13 0.890
  < median(15–52) 65 17 10 24 14  
neutropenia (days) 12–179 (61) 15–150 (65.5) 12–168 (57.0) 18–122 (58.0) 12–179 (53.0) 0.520
  > median(62–179) 60 22 8 19 11 0.342
  < median(12–61) 64 14 10 24 16  
lineage
 AML 102 31 15 33 23 0.729
 ALL 22 5 3 10 4  
prophylaxis
 FLCZ only 69 22 14 22 11 0.082
 mold-active agent 55 14 4 21 16  
 ITCZ 6 3 0 1 2  
 VRCZ 5 1 1 1 2  
 MCFG 50 12 3 21 14  
 CPFG 1 0 0 0 1  
 AMB 1 1 0 0 0  
 L-AMB 5 0 1 3 1  
treatment response after induction chemotherapy
 CR 76 21 11 24 20 0.677
 CRi 3 1 1 1 0  
 non-CR 45 14 6 18 7  
median follow-up of event free survivors (days) 139.0 (27–330) 132.5 (29–236) 149.0 (27–330) 139.0 (42–261) 135.0 (41–272) 0.963
  1. Note. AML denotes acute myelogenous leukemia; ALL acute lymphoblastic leukemia, FLCZ fluconazole, ITCZ itraconazole, VRCZ voriconazole, MCFG micafungin, CPFG caspofungin, AMB amphotericin b, L-AMB liposomal amphotericin b, CR complete remission, CRi complete remission with incomplete hematologic recovery